2025-10-01 - Analysis Report
Okay, here's a comprehensive analysis of Eli Lilly and Co (LLY), incorporating the data you provided. The report is written in English and includes numerical summaries followed by analysis.

**Eli Lilly and Co (LLY) Stock Analysis**

Eli Lilly and Company is a pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products worldwide.

**1. Performance Relative to S&P 500 (VOO)**

*   **LLY Cumulative Return:** 180.12%
*   **VOO Cumulative Return:** 97.56%
*   **Absolute Divergence:** 114.2
*   **Relative Divergence:** 47.9 (Indicates LLY is performing in the upper range of its historical outperformance relative to VOO).

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the period examined.  The relative divergence suggests that the outperformance is substantial compared to its historical range.

**Alpha, Beta Analysis**

| Year       | CAGR  | MDD   | Alpha  | Beta  | Cap(B) |
|------------|-------|-------|--------|-------|--------|
| 2015-2017  | 11.0% | 76.1% | -17.0% | -0.0  | 75.8   |
| 2016-2018  | 39.0% | 68.9% | 24.0%  | -0.0  | 103.8  |
| 2017-2019  | 41.0% | 68.9% | 19.0%  | 0.4   | 117.9  |
| 2018-2020  | 34.0% | 79.8% | 10.0%  | 0.4   | 151.4  |
| 2019-2021  | 53.0% | 79.8% | 7.0%   | 0.5   | 247.7  |
| 2020-2022  | 64.0% | 79.8% | 65.0%  | 0.4   | 328.1  |
| 2021-2023  | 125.0% | 78.9% | 124.0% | 0.2   | 522.8  |
| 2022-2024  | 134.0% | 81.2% | 113.0% | 0.2   | 692.4  |
| 2023-2025  | 71.0% | 83.5% | 9.0%   | 0.2   | 652.6  |

**Analysis:**

*   **CAGR (Compound Annual Growth Rate):**  Shows consistently strong growth, especially in recent periods (2021-2024).
*   **MDD (Maximum Drawdown):**  Indicates the maximum potential loss from peak to trough during the period. Drawdowns are relatively high.
*   **Alpha:**  Measures the excess return compared to the benchmark. Positive alpha indicates outperformance.  Alpha is particularly strong in recent years, indicating significant value added beyond market returns.
*   **Beta:**  Measures the stock's volatility relative to the market. Beta values close to zero, indicating LLY's price is less sensitive to market movements.
*   **Cap(B):** Market capitalization in billions, showing a rapid increase over time.

**2. Recent Stock Price Movement**

*   **Current Price:** 727.68
*   **Last Market Data:** Price: 728.08, Previous Close: 726.51, Change: 0.22
*   **5-Day Moving Average:** 730.40
*   **20-Day Moving Average:** 744.67
*   **60-Day Moving Average:** 742.08

**Analysis:** The current price is slightly below the 5-day, 20-day, and 60-day moving averages, which could suggest a short-term downward trend or a potential buying opportunity if the stock is expected to rebound. The small *change* of 0.22, does not suggest any significant immediate price movement.

**3. Market Risk Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 39.08 (Approaching oversold territory, potentially signaling a buying opportunity)
*   **PPO:** -0.53 (Negative PPO suggests a potential downward trend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (Very Safe) Monthly invest 0.8% of total investment
*   **Recent (20-day) Relative Divergence Change:** -3.5 (Negative indicates a short-term decline in relative outperformance).
*   **Expected Return:** 148.9% (Long-term, relative to S&P 500).

**Analysis:**

*   The MRI indicates a high investment recommendation.
*   The RSI is below 40, suggesting the stock may be approaching oversold conditions. This could be interpreted as a potential buying signal, but should be confirmed by other indicators.
*   The negative change in relative divergence suggests that LLY's recent outperformance compared to the S&P 500 is waning.
*   The high expected return indicates strong long-term growth potential compared to the S&P 500, based on the model's projections.

**4. Recent News & Significant Events**

*   **Drug Pricing Concerns:** Trump's plan to lower U.S. drug prices could present a headwind if implemented.
*   **Analyst Optimism:** Zacks reports Wall Street analysts are optimistic about LLY.
*   **AI Spending:** Citigroup forecasts significant AI spending by Big Tech, which could indirectly benefit LLY through research and development partnerships or applications in drug discovery.
*   **Dividend Stocks:** Mentioned as a rebounding dividend stock, suggesting potential for income generation.
*   **NHS Pricing:** Pricing pressures in the UK (NHS) could negatively impact revenue.
*   **Growth Stock:** Highlighted as a growth stock, reinforcing positive growth expectations.

**Analysis:** The news is mixed. Drug pricing concerns and NHS pricing pressures present potential risks. However, analyst optimism and the potential for growth driven by AI and solid long-term growth prospects provide positive signals.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.78)
*   **Target Price:** Avg: 884.31 / High: 1190.00 / Low: 650.00

**Analysis:** Analyst consensus is strongly positive, with a "Buy" recommendation. The average target price suggests substantial upside potential from the current price.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-08-07 | 6.3   | 15.56 B$   |
| 2025-05-01 | 3.07  | 12.73 B$   |
| 2024-10-30 | 1.08  | 11.44 B$   |
| 2024-08-08 | 3.29  | 11.30 B$   |
| 2025-08-07 | 3.29  | 11.30 B$   |

**Analysis:**

*   The most recent EPS (6.3) is notably higher than previous quarters, indicating strong profitability.
*   Revenue shows a general upward trend, suggesting growth in sales.

**6. Financial Information**

**Revenue and Profitability**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |
| 2024-06-30   | $11.30B    | 80.80%        |

**Capital and Profitability**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-06-30   | $18.27B    | 30.98%   |
| 2025-03-31   | $15.76B    | 17.50%   |
| 2024-12-31   | $14.19B    | 31.07%   |
| 2024-09-30   | $14.24B    | 6.81%    |
| 2024-06-30   | $13.56B    | 21.88%   |

**Analysis:**

*   **Revenue:**  Demonstrates strong and consistent growth over the past year.
*   **Profit Margin:**  Extremely high and increasing, reflecting efficient operations and strong pricing power.
*   **Equity:**  Growing, indicating increasing book value.
*   **ROE (Return on Equity):**  Generally high, indicating efficient use of shareholder equity to generate profits.

**7. Overall Summary & Conclusion**

Eli Lilly and Co (LLY) presents a compelling investment case, supported by strong financial performance, significant outperformance relative to the S&P 500, and positive analyst sentiment.  The company is experiencing strong revenue and profit growth, with high and increasing profit margins and ROE.  While there are potential risks related to drug pricing and international pricing pressures, the positive outlook is reinforced by analyst buy ratings and high target prices. The MRI suggests it is a good investment now.

**Key Positives:**

*   **Strong Historical Outperformance:** LLY has significantly outperformed the S&P 500.
*   **Excellent Growth Metrics:**  High and growing revenue, profit margins, and ROE.
*   **Positive Analyst Sentiment:**  "Buy" consensus and high target prices.
*   **High Market Risk Indicator:** Recommends investment.
*   **High Expected Return:** Projects high long term growth.

**Potential Risks:**

*   **Drug Pricing Pressure:** Potential impact from government regulations.
*   **NHS Pricing:** Pressure on pricing in the UK market.
*   **Short-Term Price Correction:** Recent price action suggests a potential short-term downward trend.

**Recommendation:**

Based on the analysis, a long-term investment in LLY appears promising, particularly for investors seeking growth. However, potential investors should be aware of the risks associated with drug pricing regulations and recent market volatility. The potential pullback in the short term could represent a good buying opportunity.

**Disclaimer:** This is an AI-generated analysis and should not be considered financial advice. Consult with a qualified financial advisor before making any investment decisions.
